A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma

The requested reference [239a29fd76ca809bf965b3d792c085885bdcba84] no longer exists in our database. It has been replaced by the current reference: [a4dd36e27fd9b54c47efce534c268531752111d2]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic ductal adenocarcinoma (PDAC). The study consists of a safety run-in period followed by a randomized/expansion period.
Epistemonikos ID: e44fea5e86c2e1d01a85e7cdc927431803bfa908
First added on: Oct 06, 2026